Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acupressure | 3 | 2018 | 3 | 1.640 |
Why?
|
| Nausea | 3 | 2018 | 49 | 1.600 |
Why?
|
| Neoplasms | 8 | 2018 | 612 | 1.570 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 546 | 1.420 |
Why?
|
| Urogenital Neoplasms | 4 | 2010 | 6 | 1.360 |
Why?
|
| Child | 27 | 2018 | 2225 | 1.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2009 | 41 | 1.180 |
Why?
|
| Complementary Therapies | 3 | 2006 | 75 | 0.720 |
Why?
|
| Cisplatin | 2 | 2018 | 69 | 0.720 |
Why?
|
| Humans | 46 | 2018 | 29241 | 0.700 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2010 | 173 | 0.660 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 206 | 0.650 |
Why?
|
| Male | 30 | 2018 | 17877 | 0.650 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 7 | 0.650 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 6 | 0.640 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 6 | 0.640 |
Why?
|
| Hemangioendothelioma | 1 | 2018 | 11 | 0.640 |
Why?
|
| Sirolimus | 1 | 2018 | 35 | 0.640 |
Why?
|
| Antiemetics | 1 | 2017 | 5 | 0.640 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 62 | 0.620 |
Why?
|
| Wilms Tumor | 4 | 2015 | 14 | 0.620 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2010 | 28 | 0.610 |
Why?
|
| Child, Preschool | 13 | 2017 | 1170 | 0.600 |
Why?
|
| Melanoma | 1 | 2018 | 148 | 0.600 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 167 | 0.580 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2018 | 337 | 0.560 |
Why?
|
| Testicular Neoplasms | 3 | 2010 | 17 | 0.560 |
Why?
|
| Hepatoblastoma | 1 | 2015 | 1 | 0.540 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 162 | 0.540 |
Why?
|
| Neuroblastoma | 2 | 2006 | 32 | 0.530 |
Why?
|
| Catheter Ablation | 1 | 2015 | 62 | 0.510 |
Why?
|
| Referral and Consultation | 2 | 2013 | 113 | 0.500 |
Why?
|
| Rhabdomyosarcoma | 3 | 2009 | 6 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2015 | 401 | 0.480 |
Why?
|
| Leukemia | 3 | 2008 | 37 | 0.470 |
Why?
|
| Pediatrics | 2 | 2013 | 132 | 0.470 |
Why?
|
| Patient Care Team | 2 | 2016 | 124 | 0.470 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 384 | 0.460 |
Why?
|
| Infant | 10 | 2018 | 974 | 0.450 |
Why?
|
| Checklist | 1 | 2013 | 35 | 0.450 |
Why?
|
| Medical Errors | 1 | 2013 | 36 | 0.450 |
Why?
|
| Adolescent | 11 | 2018 | 3267 | 0.450 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 68 | 0.440 |
Why?
|
| Medical Oncology | 1 | 2013 | 70 | 0.440 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 163 | 0.420 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 169 | 0.420 |
Why?
|
| Female | 21 | 2018 | 18242 | 0.410 |
Why?
|
| Physicians | 1 | 2013 | 135 | 0.410 |
Why?
|
| Therapeutic Touch | 1 | 2009 | 10 | 0.340 |
Why?
|
| Chickenpox | 2 | 2005 | 4 | 0.340 |
Why?
|
| Medical Futility | 1 | 2008 | 2 | 0.340 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2008 | 4 | 0.330 |
Why?
|
| Leukocytosis | 1 | 2008 | 8 | 0.330 |
Why?
|
| Oxides | 1 | 2008 | 15 | 0.330 |
Why?
|
| Arsenicals | 1 | 2008 | 12 | 0.330 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 11 | 0.330 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2008 | 21 | 0.320 |
Why?
|
| Enchondromatosis | 1 | 2008 | 3 | 0.320 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2008 | 3 | 0.320 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2008 | 5 | 0.320 |
Why?
|
| Kidney Neoplasms | 4 | 2015 | 192 | 0.320 |
Why?
|
| Music | 1 | 2008 | 9 | 0.320 |
Why?
|
| Vomiting | 1 | 2008 | 24 | 0.320 |
Why?
|
| Bone Diseases | 1 | 2008 | 16 | 0.320 |
Why?
|
| Parent-Child Relations | 1 | 2008 | 39 | 0.310 |
Why?
|
| Paracentesis | 1 | 2007 | 3 | 0.310 |
Why?
|
| Burkitt Lymphoma | 1 | 2007 | 6 | 0.310 |
Why?
|
| Pleural Effusion | 1 | 2007 | 12 | 0.310 |
Why?
|
| Treatment Outcome | 8 | 2017 | 3108 | 0.290 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 109 | 0.290 |
Why?
|
| Attitude to Health | 1 | 2008 | 148 | 0.280 |
Why?
|
| Methylobacteriaceae | 1 | 2006 | 2 | 0.280 |
Why?
|
| Life Style | 2 | 2006 | 364 | 0.280 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 13 | 0.280 |
Why?
|
| Catheterization | 1 | 2006 | 58 | 0.280 |
Why?
|
| Propranolol | 2 | 2018 | 16 | 0.270 |
Why?
|
| Plant Preparations | 1 | 2006 | 21 | 0.270 |
Why?
|
| Skin Diseases | 1 | 2008 | 138 | 0.270 |
Why?
|
| Phytotherapy | 1 | 2006 | 38 | 0.270 |
Why?
|
| Bacteremia | 1 | 2006 | 53 | 0.270 |
Why?
|
| Prednisone | 1 | 2005 | 43 | 0.270 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 12 | 0.250 |
Why?
|
| Energy Metabolism | 1 | 2006 | 139 | 0.250 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 60 | 0.250 |
Why?
|
| Dietary Supplements | 1 | 2006 | 170 | 0.250 |
Why?
|
| Glucocorticoids | 1 | 2005 | 149 | 0.240 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2003 | 1 | 0.240 |
Why?
|
| Medulloblastoma | 1 | 2003 | 7 | 0.240 |
Why?
|
| Cerebellar Neoplasms | 1 | 2003 | 11 | 0.240 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 9 | 0.240 |
Why?
|
| Hemangioma | 2 | 2013 | 18 | 0.230 |
Why?
|
| Religion | 1 | 2003 | 30 | 0.230 |
Why?
|
| Vincristine | 2 | 2018 | 15 | 0.220 |
Why?
|
| Mutation | 2 | 2015 | 469 | 0.220 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2012 | 8 | 0.220 |
Why?
|
| Testis | 2 | 2016 | 60 | 0.210 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 525 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2114 | 0.180 |
Why?
|
| Daunorubicin | 2 | 2010 | 26 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2017 | 2027 | 0.180 |
Why?
|
| Cytarabine | 2 | 2010 | 52 | 0.180 |
Why?
|
| Prednisolone | 1 | 2018 | 10 | 0.160 |
Why?
|
| Outpatients | 2 | 2008 | 49 | 0.160 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2018 | 59 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 38 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2017 | 165 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2018 | 61 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 273 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2016 | 3122 | 0.150 |
Why?
|
| Spinal Puncture | 2 | 2008 | 20 | 0.140 |
Why?
|
| Etoposide | 2 | 2008 | 30 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 20 | 0.140 |
Why?
|
| Cryopreservation | 1 | 2016 | 42 | 0.140 |
Why?
|
| Risk Factors | 2 | 2018 | 3550 | 0.140 |
Why?
|
| Spermatogenesis | 1 | 2016 | 45 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2015 | 53 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2015 | 122 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 285 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 88 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 104 | 0.130 |
Why?
|
| Prognosis | 2 | 2010 | 1364 | 0.130 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2014 | 2 | 0.120 |
Why?
|
| Ribonuclease III | 1 | 2014 | 3 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 9 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 199 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 864 | 0.120 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 17 | 0.120 |
Why?
|
| Remission Induction | 3 | 2012 | 78 | 0.120 |
Why?
|
| Vascular Neoplasms | 1 | 2013 | 14 | 0.120 |
Why?
|
| Vascular Malformations | 1 | 2013 | 8 | 0.120 |
Why?
|
| Skin Ulcer | 1 | 2012 | 10 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 481 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 46 | 0.110 |
Why?
|
| Paresis | 1 | 2012 | 10 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 24 | 0.110 |
Why?
|
| Functional Laterality | 1 | 2012 | 59 | 0.110 |
Why?
|
| Shoulder Pain | 1 | 2012 | 10 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 836 | 0.100 |
Why?
|
| Ankle Joint | 1 | 2012 | 34 | 0.100 |
Why?
|
| Arthralgia | 1 | 2012 | 31 | 0.100 |
Why?
|
| Thioguanine | 1 | 2010 | 1 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 38 | 0.100 |
Why?
|
| Recurrence | 2 | 2008 | 235 | 0.100 |
Why?
|
| Knee Joint | 1 | 2012 | 129 | 0.100 |
Why?
|
| Injections, Spinal | 1 | 2010 | 124 | 0.090 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2010 | 3 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 9 | 0.090 |
Why?
|
| Heart Rate | 2 | 2009 | 315 | 0.090 |
Why?
|
| Fatal Outcome | 3 | 2018 | 78 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 788 | 0.090 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 4 | 0.080 |
Why?
|
| Disease Progression | 2 | 2008 | 572 | 0.080 |
Why?
|
| Gene Expression | 1 | 2010 | 333 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 321 | 0.080 |
Why?
|
| Music Therapy | 1 | 2008 | 6 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Aminoglycosides | 1 | 2008 | 6 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Mitoxantrone | 1 | 2008 | 17 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2008 | 17 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 18 | 0.080 |
Why?
|
| Remission, Spontaneous | 1 | 2008 | 14 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 36 | 0.080 |
Why?
|
| Thymoma | 1 | 2007 | 5 | 0.080 |
Why?
|
| Thymus Neoplasms | 1 | 2007 | 4 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 95 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 65 | 0.080 |
Why?
|
| Thoracic Surgery | 1 | 2007 | 5 | 0.080 |
Why?
|
| Cytological Techniques | 1 | 2007 | 19 | 0.080 |
Why?
|
| Loss of Heterozygosity | 1 | 2007 | 17 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2009 | 365 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2009 | 478 | 0.070 |
Why?
|
| Radiography | 1 | 2008 | 353 | 0.070 |
Why?
|
| Child Health Services | 1 | 2006 | 18 | 0.070 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2006 | 22 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2008 | 210 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 197 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 55 | 0.070 |
Why?
|
| Species Specificity | 1 | 2006 | 85 | 0.070 |
Why?
|
| Minerals | 1 | 2006 | 11 | 0.070 |
Why?
|
| Mind-Body Therapies | 1 | 2006 | 11 | 0.070 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 3 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 437 | 0.070 |
Why?
|
| Retinitis | 1 | 2005 | 3 | 0.070 |
Why?
|
| Probability | 1 | 2006 | 150 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2008 | 603 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 43 | 0.070 |
Why?
|
| Vitamins | 1 | 2006 | 59 | 0.070 |
Why?
|
| Health Surveys | 1 | 2006 | 191 | 0.070 |
Why?
|
| Adrenalectomy | 1 | 2004 | 29 | 0.060 |
Why?
|
| Thrombosis | 1 | 2005 | 60 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2006 | 122 | 0.060 |
Why?
|
| Lomustine | 1 | 2003 | 2 | 0.060 |
Why?
|
| Self-Help Groups | 1 | 2003 | 6 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 25 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2005 | 448 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 375 | 0.060 |
Why?
|
| Diet | 1 | 2006 | 356 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2003 | 74 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2003 | 98 | 0.060 |
Why?
|
| HIV Infections | 1 | 2007 | 370 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 24 | 0.060 |
Why?
|
| Diphtheria Toxin | 1 | 2002 | 23 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 1313 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 164 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 97 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 820 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 104 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 158 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 394 | 0.050 |
Why?
|
| Young Adult | 1 | 2008 | 2413 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 595 | 0.050 |
Why?
|
| Kidney | 1 | 2004 | 486 | 0.050 |
Why?
|
| Time Factors | 1 | 2005 | 2004 | 0.050 |
Why?
|
| North Carolina | 1 | 2003 | 1425 | 0.040 |
Why?
|
| United States | 2 | 2006 | 3648 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 493 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 871 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2016 | 16 | 0.030 |
Why?
|
| Infertility, Male | 1 | 2016 | 26 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2016 | 88 | 0.030 |
Why?
|
| Adult | 2 | 2004 | 8469 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 17 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 67 | 0.030 |
Why?
|
| Pedigree | 1 | 2014 | 133 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 43 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 862 | 0.030 |
Why?
|
| Drug Design | 1 | 2013 | 44 | 0.030 |
Why?
|
| Meningomyelocele | 1 | 2012 | 9 | 0.030 |
Why?
|
| Hypospadias | 1 | 2012 | 9 | 0.030 |
Why?
|
| Syndrome | 1 | 2012 | 66 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 54 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 520 | 0.030 |
Why?
|
| Steroids | 1 | 2012 | 36 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 298 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2010 | 12 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 45 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1219 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 89 | 0.020 |
Why?
|
| Affect | 1 | 2008 | 63 | 0.020 |
Why?
|
| Mediastinal Cyst | 1 | 2007 | 3 | 0.020 |
Why?
|
| Benzamides | 1 | 2007 | 54 | 0.020 |
Why?
|
| Piperazines | 1 | 2007 | 56 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2010 | 261 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2007 | 60 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 21 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2006 | 29 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2006 | 39 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2006 | 60 | 0.020 |
Why?
|
| Chickenpox Vaccine | 1 | 2005 | 3 | 0.020 |
Why?
|
| Acyclovir | 1 | 2005 | 8 | 0.020 |
Why?
|
| Pregnancy | 1 | 2008 | 816 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 208 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2005 | 100 | 0.020 |
Why?
|
| Diphtheria Toxoid | 1 | 2002 | 2 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2002 | 14 | 0.010 |
Why?
|
| Vaccination | 1 | 2002 | 125 | 0.010 |
Why?
|
| Aged | 1 | 2002 | 9515 | 0.010 |
Why?
|
| Middle Aged | 1 | 2002 | 10872 | 0.010 |
Why?
|